Welcome to the MDS 2021 Interactive Programme

The congress will officially run on Eastern Daylight Time Zone EDT (Toronto time zone, UTC-4)
To convert the meeting times to your local time 
Click Here

Please note that all sessions will run at their scheduled time and be followed by a LIVE Q&A at the end

     The viewing of sessions cannot be accessed from this congress calendar. All sessions are accessible via the Virtual Platform

Displaying One Session

Room
Industry Research Pipeline Sessions
Session Time
05:50 PM - 06:05 PM
Session Type
Industry Research Pipeline Sessions
Session Description
Astex Pipeline Update: Oral Hypomethylating Agents in Hematologic Malignancies and Newer Astex Agents - Supported by Astex Pharmaceuticals, Inc.

Session Description:

Since the development and FDA approval of IV decitabine in 2006 for the treatment of patients with higher risk MDS, and the EMA approval in 2012 for treatment of elderly AML patients not candidates for intensive chemotherapy, Astex Pharmaceuticals has continued to develop novel approaches to delivering hypomethylating agents, resulting in the approval of oral decitabine and cedazuridine (INQOVI) by the FDA and Health Canada in July 2020. Oral decitabine and cedazuridine is the only oral hypomethylating agent demonstrating equivalent pharmacokinetic exposure to its IV form. We will review the clinical data which led to the approval of oral decitabine and cedazuridine, including new overall survival data from the ASCERTAIN Phase 3 clinical trial, and will outline how Astex is continuing to develop the product to address the emerging new standards of care for the treatment of AML and MDS. We will also outline some of the other products being developed by Astex for the treatment of hematological malignancies and solid tumors, including an oral azacitidine and cedazuridine product which uses the same fixed dose combination concept as oral decitabine and cedazuridine to deliver an equivalent pharmacokinetic exposure to IV or SC azacitidine.

Astex Pipeline Update: Oral Hypomethylating Agents in Hematologic Malignancies and Newer Astex Agents (ID 290)

Session Type
Industry Research Pipeline Sessions
Date
09/24/2021
Session Time
05:50 PM - 06:05 PM
Room
Industry Research Pipeline Sessions
Lecture Time
05:50 PM - 05:50 PM

Supported by Astex Pharmaceuticals, Inc. (ID 291)

Session Type
Industry Research Pipeline Sessions
Date
09/24/2021
Session Time
05:50 PM - 06:05 PM
Room
Industry Research Pipeline Sessions
Lecture Time
05:50 PM - 05:50 PM

Astex Pipeline Update: Oral Hypomethylating Agents in Hematologic Malignancies and Newer Astex Agents (ID 292)

Session Type
Industry Research Pipeline Sessions
Date
09/24/2021
Session Time
05:50 PM - 06:05 PM
Room
Industry Research Pipeline Sessions
Lecture Time
05:50 PM - 06:02 PM

Live Q&A (ID 293)

Session Type
Industry Research Pipeline Sessions
Date
09/24/2021
Session Time
05:50 PM - 06:05 PM
Room
Industry Research Pipeline Sessions
Lecture Time
06:02 PM - 06:05 PM